Oncotype DX is primarily used for patients with early-stage, hormone receptor-positive, HER2-negative breast cancer. It is particularly helpful for patients with node-negative disease, but it can also be used for some patients with node-positive cancer. It assists in deciding whether to add chemotherapy to hormone therapy as part of the treatment plan.
